Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
28.49
+0.83 (3.00%)
Nov 6, 2026, 4:00 PM EST - Market closed
Amphastar Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Amphastar Pharmaceuticals stock has a consensus rating of "Hold" and an average price target of $24.5. The average 1-year stock price forecast is 14.00% lower than the current stock price, while the lowest is $20 (-29.80%) and the highest is $30 (+5.30%).
Price Target: $24.5 (-14.00%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Amphastar Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Sell Reiterates $23 | Sell | Reiterates | $23 | -19.27% | Nov 7, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $20 → $25 | Hold | Maintains | $20 → $25 | -12.25% | Nov 6, 2026 |
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Hold Maintains $30 | Hold | Maintains | $30 | +5.30% | Oct 22, 2026 |
| Barclays | Barclays | Hold Maintains $20 → $23 | Hold | Maintains | $20 → $23 | -19.27% | Aug 18, 2026 |
| Needham | Needham | Hold Maintains $20 | Hold | Maintains | $20 | -29.80% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
747.32M
from 719.89M
Increased by 3.81%
Revenue Next Year
783.99M
from 747.32M
Increased by 4.91%
EPS This Year
2.96
from 3.25
Decreased by -8.87%
EPS Next Year
3.17
from 2.96
Increased by 7.09%
EPS and Forward PE are based on non-GAAP adjusted numbers.